Mesenchymal Stem Cell-Derived Long Noncoding RNAs in Cardiac Injury and Repair

Cells. 2023 Sep 13;12(18):2268. doi: 10.3390/cells12182268.

Abstract

Cardiac injury, such as myocardial infarction and heart failure, remains a significant global health burden. The limited regenerative capacity of the adult heart poses a challenge for restoring its function after injury. Mesenchymal stem cells (MSCs) have emerged as promising candidates for cardiac regeneration due to their ability to differentiate into various cell types and secrete bioactive molecules. In recent years, attention has been given to noncoding RNAs derived from MSCs, particularly long noncoding RNAs (lncRNAs), and their potential role in cardiac injury and repair. LncRNAs are RNA molecules that do not encode proteins but play critical roles in gene regulation and cellular responses including cardiac repair and regeneration. This review focused on MSC-derived lncRNAs and their implications in cardiac regeneration, including their effects on cardiac function, myocardial remodeling, cardiomyocyte injury, and angiogenesis. Understanding the molecular mechanisms of MSC-derived lncRNAs in cardiac injury and repair may contribute to the development of novel therapeutic strategies for treating cardiovascular diseases. However, further research is needed to fully elucidate the potential of MSC-derived lncRNAs and address the challenges in this field.

Keywords: cardiac regeneration; exosome; heart failure; long noncoding RNA; mesenchymal stem cells; myocardial remodeling; noncoding RNA.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Heart Injuries*
  • Humans
  • Mesenchymal Stem Cells*
  • Myocardial Infarction* / genetics
  • Myocardial Infarction* / therapy
  • Myocytes, Cardiac
  • RNA, Long Noncoding* / genetics

Substances

  • RNA, Long Noncoding

Grants and funding

This work was supported by funding from the American Heart Association Grant #940594/Narasimman Gurusamy/2022.